scholarly journals Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer

2018 ◽  
Author(s):  
M. Kimura ◽  
F. Yasue ◽  
E. Usami ◽  
S. Kawachi ◽  
M. Iwai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Targeted Drugs ◽  
Small Cell Lung ◽  
First Line

scholarly journals First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer

2019 ◽  
Vol 18 ◽  
pp. 100113 ◽  
Author(s):  
Kazuma Kishi ◽  
Hiroshi Sakai ◽  
Takashi Seto ◽  
Toshiyuki Kozuki ◽  
Makoto Nishio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document